Immupharma PLC Euronext Delisting (6313N)
01 Octubre 2021 - 12:59AM
UK Regulatory
TIDMIMM
RNS Number : 6313N
Immupharma PLC
01 October 2021
RNS | 1 OCTOBER 2021
ImmuPharma PLC
("ImmuPharma", the "Company" or the "Group")
EURONEXT DELISTING
Date: 18 October 2021
ImmuPharma PLC (LSE:IMM; Euronext Growth Brussels: ALIMM), the
specialist drug discovery and development company, provides an
update on its delisting from the Euronext Growth Brussels market,
where it has a dual listing with AIM. This proposed de-listing from
Euronext Growth Brussels was recently confirmed in the Company's
'Corporate Update' announcement on 29 September 2021.
The Company has received confirmation that the Euronext Listing
Board has approved its voluntary delisting request from Euronext
Growth Brussels.
The timeframe of the de-listing has been agreed with Euronext.
It is envisaged that the shares of ImmuPharma (ISIN: GB0033711010)
will be removed from trading on Euronext Growth Brussels, as from
the 18 October 2021.
Below is a summary of the delisting schedule as disclosed:
DATE EVENT
15 October Last day of trading of ImmuPharma's shares on
2021 Euronext Growth Brussels
---------------------------------------------------
18 October ImmuPharma's shares de-listed from Euronext Growth
2021 Brussels
---------------------------------------------------
End
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED
UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014
WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL)
ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A
REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO
BE IN THE PUBLIC DOMAIN.
For further information please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chief Executive Officer &
Chairman + 44 (0) 207 152 4080
Lisa Baderoon, Head of Investor Relations
& Non-Executive Director + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 203 36 8 3550
Stanford Capital Partners (Joint Broker)
Patrick Claridge +44 20 3650 3650
John Howes
Bob Pountney
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
4Reliance (Euronext Growth Listing Sponsor) +32 (0) 2 747 02 60
Jean-Charles Snoy
Degroof Petercam (Liquidity Provider) +32 (0) 2 287 95 34
Erik De Clippel
Backstage Communication
Olivier Duquaine +32 (0) 477 504 784
Gunther De Backer +32 (0) 475 903 909
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases and anti-infectives.
The lead program, Lupuzor(TM), is a first-in class autophagy
immunomodulator which is in Phase 3 for the treatment of lupus and
preclinical analysis suggest therapeutic activity for many other
autoimmune diseases that share the same autophagy mechanism of
action. ImmuPharma and Avion Pharmaceuticals signed on 28 November
2019, an exclusive licence and development agreement and trademark
agreement for Lupuzor(TM) to fund a new international Phase 3 trial
for Lupuzor(TM) and commercialise in the US.
For additional information about ImmuPharma please visit
www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code:
213800VZKGHXC7VUS895.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDKKBBABKDDCN
(END) Dow Jones Newswires
October 01, 2021 01:59 ET (05:59 GMT)
Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024